Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 PK drug–drug interaction of TAK-438 triple therapies in healthy Japanese males
jRCT2080223048Phase 3
- Sponsor
- Takeda
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vonoprazan in Helicobacter pylori infection and Peptic ulcer disease (PUD) (6 arms), sponsored by Takeda. Primary endpoint: Primary pharmacokinetic endpoints.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infectionPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on jRCT2080223048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223048.